A minireview of CYP2C9 AND CYP2C19 Single Nucleotide Polymorphisms (SNPs) among Malaysian populations
It has been recognized extensively that studies of pharmacogenetics provide massive examples of causal relationship between genotypes and drug effectiveness to account for interindividual phenotypic variations in drug therapy. In most cases, cytochrome P450 (CYP) polymorphisms are one of the maj...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | http://eprints.unisza.edu.my/5686/1/FH02-FP-18-12627.pdf http://eprints.unisza.edu.my/5686/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | It has been recognized extensively that studies of
pharmacogenetics provide massive examples of causal relationship
between genotypes and drug effectiveness to account for
interindividual phenotypic variations in drug therapy. In most cases,
cytochrome P450 (CYP) polymorphisms are one of the major
variables that affecting those drug plasma concentration, drug
detoxification and drug activation in humans. Thus, understanding of
CYP polymorphisms can be crucially valuable in order to allow early
and more accurate drug dosage prediction and improve the drug
response accordingly. Despite the high level of homologous amino
acid sequences, CYP2C9 and CYP2C19 genes are among the most
important CYP genes which metabolize a wide range of clinically
therapeutic drugs. Several critical reviews have been published
relating to the aforementioned genes. However, this minireview aims
to systematically merge reported studies on the SNPs frequencies of
both genes concentrating only on Malaysian population. It is hoped
that, the minireview can be an opener for new opportunities to
reevaluate the evidence on the prevalence of CYP2C genes as a
potential genetic factor influencing a particular drug efficacy and
safety among Malaysian. Such evaluation can be developed to the
next level of early prediction of better and specific drug treatment,
thereby improving the drug response while helping the government in
minimising the drug expenditures. |
---|